Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT

by Falzetti, F , Sayer, H , Yakoub-Agha, I , Bouabdallah, R , Salles, G , Sellner, L , Scime, R , Kobbe, G , Vallisa, D , Nicolas-Virelizier, E , Faber, E , Zuffa, E , Dreger, P , Choquet, S , Finel, H , de Rosa, G , Delmer, A , Boumendil, A , Finke, J , Amorim, S , Facchini, L , Ferrara, F , Sureda, A

in 692/308/2779 / 692/699/1541/1990/291/1556 / 692/699/1541/1990/291/1621/1915 / Adolescent / Adult / Aged / Analysis / Antineoplastic Combined Chemotherapy Protocols - administration & dosage / Autografts / B-cell lymphoma / Bone marrow / Cancer / Care and treatment / Carmustine - administration & dosage / Cell Biology / Central nervous system / Clinical trials / Complications / Cytarabine / Cytarabine - administration & dosage / Disease-Free Survival / Dosage and administration / Etoposide / Female / Hematology / Hodgkin's lymphoma / Humans / Internal Medicine / Life Sciences / Lymphocytes B / Lymphoma / Lymphoma - mortality / Lymphoma - therapy / Male / Medicine / Medicine & Public Health / Melphalan / Melphalan - administration & dosage / Middle Aged / Non-Hodgkin's lymphomas / original-article / Patients / Podophyllotoxin - administration & dosage / Public Health / Registries / Retrospective Studies / Stem Cell Transplantation / Stem Cells / Survival / Survival Rate / Thiotepa / Thiotepa - administration & dosage / Toxicity / Transplantation

2016

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT

2016

Confirm

Do you wish to request the book?

Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT

2016

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT

Falzetti, F,

Sayer, H,

Yakoub-Agha, I,

Bouabdallah, R,

Salles, G,

Sellner, L,

Scime, R,

Kobbe, G,

Vallisa, D,

Nicolas-Virelizier, E,

Faber, E,

Zuffa, E,

Dreger, P,

Choquet, S,

Finel, H,

de Rosa, G,

Delmer, A,

Boumendil, A,

Finke, J,

Amorim, S,

Facchini, L,

Ferrara, F,

Sureda, A

2016

Overview

Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse. In this registry-based retrospective study, we evaluated potential risks and benefits of thiotepa-based preparative regimens compared with BEAM (carmustine, etoposide, cytarabine, melphalan) in auto-SCT for diffuse large B-cell lymphoma (DLBCL, excluding PCNSL), follicular lymphoma (FL) or Hodgkin lymphoma (HL). A total of 14 544 patients (589 thiotepa and 13 955 BEAM) met the eligibility criteria, and 535 thiotepa- and 1031 BEAM-treated patients were matched in a 1:2 ratio for final comparison. No significant differences between thiotepa and BEAM groups for any survival end point were identified in the whole sample or disease entity subsets. For a more detailed analysis, 47 TEAM (thiotepa, etoposide, cytarabine, melphalan)-treated patients were compared with 75 matched BEAM patients with additional collection of toxicity data. Again, there were no significant differences between the two groups for any survival end point. In addition, the frequency of common infectious and non-infectious complications including secondary malignancies was comparable between TEAM and BEAM. These results indicate that thiotepa-based high-dose therapy might be a valuable alternative to BEAM in DLBCL, HL and FL. Further evaluation by prospective clinical trials is warranted.

Share this book

Add to My Shelf

Publisher

Nature Publishing Group UK,Nature Publishing Group

Subject

692/308/2779

/ 692/699/1541/1990/291/1556

/ 692/699/1541/1990/291/1621/1915

/ Adolescent

/ Adult

/ Aged

/ Analysis